Diaceutics (LON:DXRX) Trading Up 1.8% - Here's Why

Key Points

• Diaceutics PLC's share price increased by 1.8%, reaching GBX 140 ($1.90), with trading volume significantly up at approximately 361,589 shares, a 142% increase over average daily volume.
• Canaccord Genuity maintains a "buy" rating with a target price of GBX 180 ($2.44), while Royal Bank of Canada has lowered its target from GBX 195 to GBX 185 ($2.51), rating the stock as "outperform."
• Diaceutics reported a negative EPS of GBX (2.02) ($0.03) for its last quarterly earnings and has a market cap of £118.15 million, reflecting ongoing volatility in its financial performance.

Diaceutics PLC (LON:DXRX - Get Free Report)'s share price was up 1.8% during trading on Wednesday . The company traded as high as GBX 140 ($1.90) and last traded at GBX 140 ($1.90). Approximately 361,589 shares were traded during mid-day trading, an increase of 142% from the average daily volume of 149,681 shares. The stock had previously closed at GBX 137.50 ($1.87).

Analysts Set New Price Targets

DXRX has been the subject of a number of research analyst reports. Canaccord Genuity Group reiterated a "buy" rating and issued a GBX 180 ($2.44) target price on shares of Diaceutics in a report on Tuesday, July 22nd. Royal Bank Of Canada decreased their price target on Diaceutics from GBX 195 ($2.65) to GBX 185 ($2.51) and set an "outperform" rating for the company in a report on Thursday, July 10th.

Diaceutics Stock Performance

The company has a 50-day simple moving average of GBX 125.40 and a two-hundred day simple moving average of GBX 127.42. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 0.39. The firm has a market cap of £118.15 million, a PE ratio of -41.52 and a beta of 0.58.

Diaceutics (LON:DXRX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported GBX (2.02) (($0.03)) EPS for the quarter. Diaceutics had a negative net margin of 10.90% and a negative return on equity of 7.15%. As a group, equities research analysts forecast that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.